/XRAY
XRAY Stock - DENTSPLY SIRONA Inc.
Healthcare|Medical - Instruments & SuppliesNASDAQ
$11.21-0.62%
$0.07 (-0.62%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.16
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+27.8%upside
Target: $14.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XRAY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.10 – $11.32
TARGET (TP)$14.33
STOP LOSS$10.31
RISK/REWARD1:3.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.02
52W High$20.60
52W Low$9.85
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.79B | $3.96B | $3.92B | $4.23B | $3.34B |
| Gross Profit | $1.96B | $2.09B | $2.13B | $2.35B | $1.66B |
| Gross Margin | 51.6% | 52.6% | 54.2% | 55.5% | 49.6% |
| Operating Income | $-879,000,000 | $-85,000,000 | $-937,000,000 | $608.00M | $-3,000,000 |
| Net Income | $-910,000,000 | $-132,000,000 | $-950,000,000 | $411.00M | $-73,000,000 |
| Net Margin | -24.0% | -3.3% | -24.2% | 9.7% | -2.2% |
| EPS | $-4.48 | $-0.62 | $-4.41 | $1.88 | $-0.38 |
Company Overview
DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables. The Technologies & Equipment segment provides dental equipment, such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners and specialists; dental CAD/CAM technologies for dental offices to support various digital dental procedures, including dental restorations; dentist-directed clear aligner solutions, SureSmile, and direct-to-consumer clear aligner solutions, as well as high frequency vibration technology device; implants; and urology catheters and other healthcare-related consumable products. The Consumables segment offers endodontic products comprising drills, filers, sealers, irrigation needles, and other tools or single-use solutions, which support root canal procedures; restorative products that include artificial teeth, dental ceramics, digital dentures, precious metal dental alloys, and crown and bridge porcelain products. It also provides small equipment products, which comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, impression materials, teeth whiteners, and topical fluoride. The company was founded in 1877 and is headquartered in Charlotte, North Carolina.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
40%
Hold / Neutral
8
53%
Sell / Underperform
1
7%
Analyst Consensus🔴 Bearish
6 Bullish9 Neutral/Bearish
Price Targets
$31
Average Target
↑ 178.5% Upside
Now
$12
Low
$31
Average
$49
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Underweight | $12 |
| November 7th 2025 | William Blair | Downgrade | Market Perform | - |
| April 15th 2025 | Morgan Stanley | Downgrade | Equal Weight | $14 |
| March 13th 2025 | Needham | Downgrade | Hold | - |
| February 14th 2025 | Wells Fargo | Initiation | Equal Weight | $20 |
| January 23rd 2025 | Jefferies | Downgrade | Hold | $20← $30 |
| January 7th 2025 | Evercore ISI | Downgrade | In-line | $20 |
| December 4th 2024 | Mizuho | Initiation | Neutral | $21 |
| November 7th 2024 | Leerink Partners | Downgrade | Market Perform | - |
| October 25th 2024 | Needham | Reiterated | Buy | $29← $34 |
| August 20th 2024 | Needham | Reiterated | Buy | $34 |
| February 26th 2024 | Leerink Partners | Initiation | Outperform | $42 |
| November 16th 2023 | Needham | Initiation | Buy | $35 |
| November 10th 2023 | William Blair | Upgrade | Outperform | - |
| January 12th 2023 | William Blair | Upgrade | Market Perform | - |
Earnings History & Surprises
XRAYBeat Rate
57%
Last 14 quarters
Avg Surprise
-0.4%
EPS vs Estimate
Beats / Misses
8/5
1 met exactly
Latest EPS
$0.37
Q4 2025
EPS Surprise History
Q1 24
+2.3%
$0.44vs$0.43
Q2 24
0.0%
$0.42vs$0.42
Q3 24
-2.0%
$0.49vs$0.50
Q4 24
+4.2%
$0.50vs$0.48
Q1 25
-44.7%
$0.26vs$0.47
Q2 25
+48.3%
$0.43vs$0.29
Q3 25
+4.0%
$0.52vs$0.50
Q4 25
-17.8%
$0.37vs$0.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.28 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.45 | $0.37 | -17.8% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $0.50 | $0.52 | +4.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.29 | $0.43 | +48.3% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $0.47 | $0.26 | -44.7% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.48 | $0.50 | +4.2% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $0.50 | $0.49 | -2.0% | ✗ MISS |
Q2 2024 | May 2, 2024 | $0.42 | $0.42 | 0.0% | = MET |
Q1 2024 | Feb 29, 2024 | $0.43 | $0.44 | +2.3% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.48 | $0.49 | +2.1% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | — | $-0.07 | — | — |
Q3 2023 | Aug 7, 2023 | — | $-0.09 | — | — |
Q3 2023 | Aug 2, 2023 | $0.43 | $0.51 | +18.6% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $0.59 | $0.41 | -30.5% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | — | $0.32 | — | — |
Q3 2022 | Sep 24, 2022 | — | $0.34 | — | — |
Q1 2022 | Feb 28, 2022 | $0.79 | $0.76 | -3.8% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $0.65 | $0.68 | +4.6% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $0.65 | $0.71 | +9.2% | ✓ BEAT |
Latest News
Barrington Research Maintains Outperform on Dentsply Sirona, Maintains $14 Price Target
➖ NeutralBenzinga•Dec 16, 2025, 03:30 PM
Baird Maintains Neutral on Dentsply Sirona, Lowers Price Target to $12
➖ NeutralBenzinga•Dec 16, 2025, 11:28 AM
Barclays Initiates Coverage On Dentsply Sirona with Underweight Rating, Announces Price Target of $12
📉 NegativeBenzinga•Dec 9, 2025, 03:38 PM•Also:
Barrington Research Maintains Outperform on Dentsply Sirona, Lowers Price Target to $14
➖ NeutralBenzinga•Nov 10, 2025, 01:28 PM
Dentsply Sirona's CFO Matthew Garth Steps Down Effective November 5, 2025
📉 NegativeBenzinga•Nov 7, 2025, 09:52 PM
JP Morgan Maintains Neutral on Dentsply Sirona, Lowers Price Target to $12
➖ NeutralBenzinga•Nov 7, 2025, 08:17 PM
Wells Fargo Maintains Equal-Weight on Dentsply Sirona, Lowers Price Target to $12
📉 NegativeBenzinga•Nov 7, 2025, 06:50 PM
William Blair Downgrades Dentsply Sirona to Market Perform
📉 NegativeBenzinga•Nov 7, 2025, 12:38 PM
Dentsply Sirona Lowers FY2025 Adj EPS Guidance from $1.80-$2.00 to $1.60 vs $1.88 Est; Affirms FY2025 Sales Guidance of $3.600B-$3.700B vs $3.653B Est
📉 NegativeBenzinga•Nov 6, 2025, 01:03 PM
Dentsply Sirona Q3 Adj. EPS $0.37 Misses $0.45 Estimate, Sales $904.000M Beat $896.710M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 01:01 PM
UBS Maintains Buy on Dentsply Sirona, Lowers Price Target to $23
➖ NeutralBenzinga•Oct 28, 2025, 05:58 PM
Dentsply Sirona says SEC ends probe with no action; stock rises
📈 PositiveSeeking Alpha•Oct 15, 2025, 08:24 AM
Dentsply Sirona Says SEC Concludes Investigation Of Dentsply Sirona; SEC Does Not Recommend Enforcement Action Against Co; SEC Has Concluded Its Investigation Of Company Commenced In May 2022
📈 PositiveBenzinga•Oct 14, 2025, 08:34 PM
Evercore ISI Group Maintains In-Line on Dentsply Sirona, Lowers Price Target to $13
➖ NeutralBenzinga•Oct 8, 2025, 01:26 PM
Needham Reiterates Hold on Dentsply Sironato Hold
➖ NeutralBenzinga•Sep 26, 2025, 11:21 AM
DENTSPLY SIRONA Decides To Retain Wellspect Healthcare After Strategic Review
➖ NeutralBenzinga•Sep 8, 2025, 01:42 PM
Dentsply Sirona Grows Margins Amid Slump
📈 PositiveThe Motley Fool•Sep 2, 2025, 02:43 PM
Frequently Asked Questions about XRAY
What is XRAY's current stock price?
DENTSPLY SIRONA Inc. (XRAY) is currently trading at $11.21 per share. The stock has moved -0.62% today.
What is the analyst price target for XRAY?
The average analyst price target for XRAY is $14.33, based on 1 analyst.
What sector is DENTSPLY SIRONA Inc. in?
DENTSPLY SIRONA Inc. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.
What is XRAY's market cap?
DENTSPLY SIRONA Inc. has a market capitalization of $2.24 billion, making it a mid-cap company.
Does XRAY pay dividends?
No, DENTSPLY SIRONA Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
BHC
Bausch Health Companies Inc.
$6.88
Mkt Cap: $2.5B
CON
Concentra Group Holdings Parent, Inc.
$19.43
Mkt Cap: $2.5B
HAE
Haemonetics Corporation
$80.21
Mkt Cap: $3.9B
ICUI
ICU Medical, Inc.
$145.15
Mkt Cap: $3.6B
LMAT
LeMaitre Vascular, Inc.
$84.96
Mkt Cap: $1.9B
QDEL
QuidelOrtho Corporation
$28.95
Mkt Cap: $2.0B
RXRX
Recursion Pharmaceuticals, Inc.
$4.26
Mkt Cap: $1.7B
WRBY
Warby Parker Inc.
$26.39
Mkt Cap: $3.2B
Explore stocks similar to XRAY for comparison